Search

History and Clinical Findings: Primary glucocorticoid resistance syndrome (PGRS) is a rare condition characterized by hypercortisolism without Cushing's syndrome. This report describes a 7-year-old boy of PGRS with pseudo-precocious puberty and galactorrhea as the main manifestation. His height was 135 cm and body weight was 31 kg. Pigmentation could be seen in the skin, mammary areola and penis. He had hirsutism, low hair line, coarse voice, Tanner stage 3 pubic hair, penis in adult form, accelerated linear growth, and advanced bone age (13 yr.), but normal (for age) testes. Furthermore, he had mammoplasia and galactorrhea. There were no features of glucocorticoid (GC) excess., Laboratory Findings: Hepatic function was impaired (ALT 1426 IU/L, AST 611 IU/L) with no definite causes. Serum cortisol concentration was 1294 nmol/L, 777 nmol/L, 199.3 nmol/L at 8:00, 16:00 and 24:00 respectively. Plasma adrenocorticotropic hormone (ACTH) was normal or a little higher (43.9-80 ng/L). Urinary-free cortisol (UFC) was normal (55.5-62.4 microg/24 h). Serum estradiol (E2), progesterone (P), testosterone (T), luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were normal. Serum dehydroepiandrosterone sulfate (DHEAS, 60 microg/dL) and serum prolactin (PRL, 58.7-183.9 ng/mL) level were high, urinary dehydroepiandrosterone (DHEA) level was also elevated (0.96-3.2 mg/mL). Gonadotrophin hormone-releasing hormone (GnRH) stimulation test was negative. Serum cortisol responded normally to insulin-induced hypoglycemia. However, serum cortisol and plasma ACTH concentration was suppressed to more than 50% by 0.5 mg dexamethasone (DEX). The diagnosis of PGRS was made. TREATMENT AND FOLLOW-UP: The patient received a treatment of 0.75-1.0 mg/d DEX. Because of galactorrhea, bromocriptine was given by 1.25-3.75 mg/d. After 24 months follow-up, the pigmentation was relieved and galactorrhea disappeared. No advanced development of the external genitalia and breast was found. The acceleration of the bone age was also slowed down. But he still had obvious hirsutism. No side effect of DEX was found., Conclusion: PGRS may present with pseudo-precocious puberty and galactorrhea. The aim of treatment in glucocorticoid resistance is to suppress the excessive secretion of ACTH and the increased production of adrenal androgens. The administration of synthetic GC with minimal intrinsic mineralocorticoid activity, such as DEX, provides a rational treatment for PGRS. Long-term DEX treatment should be individualized and carefully titrated based on the clinical manifestations and biochemical profile in order to control the clinical manifestations of the disease.

Background & Objective: Garlic and the organosulfer compound from garlic have antitumor effects, but the mechanisms still remain unclear. This study was to investigate the changes and significance of caspase-3 activity in diallyl trisulfide (DATS)-induced apoptosis of human gastric cancer cell line MGC803., Methods: Effects of DATS on the apoptosis of MGC803 cells and the change of activated caspase-3 were observed under a fluorescent and an electron microscopy, and detected by flow cytometry and Western blot., Results: After incubation with DATS, MGC803 cells showed typical apoptotic morphologic changes, and the apoptosis rate increased significantly. DATS activated caspase-3 in a time-dependent manner: the positive rates of activated caspase-3 were 1.9%, 3.0%, 7.3%, 14.4%, and 27.6% respectively in MGC-803 cells treated with 12 mg/L DATS for 0, 4, 8, 12 and 24 h. When treated with 12 mg/L DATS for 24 h, the apoptosis rate was significantly lower in the cells with pretreatment of Ac-DEVD-CHO (a caspase-3 inhibitor) than in the cells without pretreatment (5.1% vs. 23.0%, P<0.01), indicating that Ac-DEVD-CHO efficiently attenuated DATS-induced apoptosis of MGC803 cells. Moreover, pro-caspase-3 was hydrolyzed and activated in DATS-treated MGC803 cells., Conclusion: DATS induces apoptosis in MGC803 cells which may be through the activation of caspase-3 pathway.

Background & Objective: Diallyl disulfide (DADS) can inhibit growth of various cancer cell lines in vitro, but little is known about its in vivo antitumor effect. This study was designed to investigate effect of DADS on growth of human gastric carcinoma MGC803 cells xenograft in BALB/C nude mice., Methods: MGC803 cells, with or without 1-day treatment of DADS (30 mg/L), were subcutaneously transplanted into the right axial regions of nude mice. The xenograft tumor growth in mice was observed after in vitro treatment or intraperitoneal injection of DADS. Proliferating cell nuclear antigen (PCNA) expression was detected by Western blot., Results: No xenograft tumor was observed in the nude mice inoculated with DADS-treated MGC803 cells. When injected with 50, 100, and 200 mg/kg of DADS, the inhibition rate of tumor growth in the nude mice inoculated with untreated MGC803 cells were 27.8%, 66.1%, and 73.0%; the expression of PCNA was inhibited., Conclusion: DADS could suppress incidence of human gastric carcinoma xenograft in BALB/C nude mice, and inhibit growth of transplanted tumor.